ArticleAnnals of medicine and surgery (2012)2025
Outcomes and prognostic factors of tonsillar Kaposi sarcoma in the United States SEER Database.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary tonsillar kaposi sarcoma in an HIV-negative, immunocompetent patient: A case-based review.Irish journal of medical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tonsillar Kaposi sarcoma (KS) is an extremely rare manifestation of KS, a neoplasm associated with human herpesvirus-8 and often linked to immunocompromised individuals. This study aims to analyze the outcomes and prognostic factors of tonsillar KS using data from the SEER (Surveillance, Epidemiology, and End Results) database, covering cases from 2000 to 2020. A total of 42 patients were identified, with the vast majority being male (97.6%) and a mean age of 40.1 years. Tumors were primarily localized (42.9%), and treatment modalities varied, with radiation therapy being the most common (38.1%), followed by chemotherapy (21.4%) and surgery (19.0%). Survival analysis showed that 21.4% of patients had died by the last follow-up, but the median survival time was not reached, indicating a relatively favorable prognosis. No statistically significant survival differences were observed based on treatment modality or other demographic factors, though there were trends towards worse outcomes for patients with regional disease and longer delays in treatment initiation. The study highlights the rarity of tonsillar KS, its demographic profile, and suggests a generally positive prognosis, although further research is needed to optimize treatment strategies for this rare form of KS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.